Hospices Civils de Lyon, Hôpital Lyon-Sud, Department of Hematology, Pierre-Bénite France and Université de Lyon, Université Claude Bernard, Faculté de Médecine Lyon-Sud, 165, chemin du Grand Revoyet, 69495 cedex, Oullins, France.
Hospices Civils de Lyon, Hôpital Lyon-Sud, Department of Hematology, Pierre-Bénite France and Université de Lyon, Université Claude Bernard, Faculté de Médecine Lyon-Sud, 165, chemin du Grand Revoyet, 69495 cedex, Oullins, France.
Hematol Oncol Clin North Am. 2020 Aug;34(4):689-699. doi: 10.1016/j.hoc.2020.02.005. Epub 2020 May 5.
Because patients with follicular lymphoma (FL) usually experience repeated disease recurrences, maintenance treatment is an attractive option to prolong remission after induction therapy. Rituximab maintenance therapy has been shown in multiple randomized studies to significantly improve progression-free survival in FL with both low and high tumor burden after induction therapy, independently of patient and disease characteristics. Several questions regarding the use of antibody directed against CD20 (anti-CD20) maintenance remain open, including the optimal antibody administration schedule and duration, the risk/benefit ratio of maintenance in the context of previous bendamustine administration, and its cost-effectiveness.
由于滤泡性淋巴瘤（FL）患者通常会经历多次疾病复发，因此维持治疗是一种有吸引力的选择，可以在诱导治疗后延长缓解期。多项随机研究表明，利妥昔单抗维持治疗可显著改善诱导治疗后肿瘤负荷低和高的 FL 患者的无进展生存期，且与患者和疾病特征无关。关于使用针对 CD20 的抗体（抗 CD20）维持治疗仍存在一些问题，包括最佳抗体给药方案和持续时间、在先前使用苯达莫司汀的情况下维持治疗的风险/效益比，以及其成本效益。
